A medicated patch & hypoallergenic peanuts reduce the nut’s allergy threat

By Elizabeth Crawford contact

- Last updated on GMT

Medicated patch, hypoallergenic peanuts reduce nut’s allergy threat

Related tags: Allergy, Peanut, Asthma

Two new treatments – one for people and one for peanuts – could significantly reduce the potentially life-threatening risk the legumes pose to the 2.8 million Americans who are allergic to them. 

FDA and the European Medicines Agency recently gave the biotech company DBV Technologies a green light to launch Phase III clinical trials of its Viaskin Peanut allergy treatment patch. The trials, which will be in the fourth quarter of 2015 will focus on children 4 to 11 years old, the company announced June 23.

The company also hopes to test the patch, which allows medicine to be absorbed through intact skin and avoid blood transfer, on younger and older patients as well – a proposal it hopes to discuss with FDA in the back half of 2015.

Success will be measured by how many children who have allergic reaction to 10 mg or less of peanut protein can tolerate at least 300 mg of peanut protein after 12 months of treatment. In addition, the company hopes children who can tolerate 10 mg or more of peanut protein at baseline will be able to tolerate up to 1,000 mg after a year of treatment, according to the firm, which is developing similar technology for milk allergies, too.

The research also will seek to establish how much or little peanut protein it takes to trigger a reaction after a year verses a placebo, it added.

Creating hypoallergenic peanuts

On the food side, scientists at North Carolina A & T University discovered a way to remover 98% of the allergens from peanuts without affecting the flavor, the U.S. Department of Agriculture touts in its 2014 Annual Report on Technology Transfer published June 24.

USDA explains in the report that “researchers found by soaking roasted peanuts that have been shelled and skinned in a solution containing food-grade enzymes, they can virtually reduce or eliminate key allergens.”

Specifically, the process reduces the allergen Ara h1 to undetectable levels, and Ara h2 by up to 98%, according to the school.

The non-GMO peanuts can be eaten whole, in pieces or ground into a powder, and are ready for product development, Xemerge, which signed an exclusive licensing agreement for the patented process of making hypoallergenic peanuts, announced last October.

“Because of this work, hypoallergenic peanut products are expected to his store shelves soon,”​ USDA said in the report. 

Related news

Show more

Related products

show more

Snacking: Consumers want more than guilty pleasure

Snacking: Consumers want more than guilty pleasure

American Egg Board | 06-May-2019 | Product Brochure

Snacks crept in from the dark shadows of guilty pleasure to grab a dominant and even bold role in America’s dining habits. Far from the furtive midnight...

Plant-based meat alternatives market motivators

Plant-based meat alternatives market motivators

DuPont Nutrition & Health | 01-Apr-2019 | Technical / White Paper

Market analysis shows steady growth in the plant-based meat alternatives segment over the past few years as consumers eat more plant-based foods. The reason...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars